Market Overview:
The global cefprozil API market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of infectious diseases, increasing demand for cefprozil tablets and suspension, and growing investments by pharmaceutical companies in R&D activities. However, the high cost of cefprozil API is expected to restrain the growth of this market during the forecast period. On the basis of type, the global cefprozil API market can be segmented into purity ≥ 98 % and purity ≥ 99 %. The purity ≥ 98 % segment is expected to account for a larger share of this market than the purity ≥ 99 % segment during the forecast period. On the basis of application, this market can be divided into cefprozil tablets and suspension.
Product Definition:
Cefprozil API is a cephalosporin antibiotic used in the treatment of certain bacterial infections. It is important because it can help to fight off bacteria that may cause infection.
Purity ≥ 98 %:
Cefprozil is a cephalosporin antibiotic drug, which is used to treat bacterial infections of the skin and soft tissue. It works by killing the bacteria that causes the infection. Cephalosporin antibiotics are widely prescribed for acute bacterial skin and soft tissue infections including impetigo, cellulitis, furunculosis, necrotizing pneumonia (Necrotizing Infectious Disease), burn wound infections and surgical site infection.
Purity ≥ 99 %:
Cefprozil is a cephalosporin antibiotic drug and it's used for the treatment of bacterial infections in many body parts including kidney, liver, bladder, and heart. The drug has no serious side effects but may cause mild symptoms such as stomach pain, nausea & vomiting.
Application Insights:
Cefprozil tablets were the largest application segment and accounted for a revenue share of 69.1% in 2017. The product is used to treat bacterial infections caused by susceptible strains of C. difficile, H. influenzae, S.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers coupled with high healthcare expenditure levels in this region is expected to drive the demand for cefprozil APIs. In addition, increasing prevalence of multi-drug resistant tuberculosis (MDR-TB) is anticipated to further boost product demand over the forecast period.
Asia Pacific is estimated to be one of the fastest growing regions during the forecast period owing to rising healthcare expenditure levels and improving economic conditions in emerging countries such as China and India. Furthermore, an increase in foreign direct investment by international drug manufacturers has resulted into improvement on production capabilities which will also drive growth over next eight years.
Growth Factors:
- Increasing prevalence of bacterial infections: The global incidence of bacterial infections is increasing due to the growing population, changing lifestyle, and increasing travel. This is expected to drive the demand for cefprozil API in the coming years.
- Rising demand for cephalosporins: Cephalosporins are a class of antibiotics that are used to treat a wide range of bacterial infections. The growing demand for cephalosporins is expected to boost the market for cefprozil API in the coming years.
- Growing awareness about antibiotic resistance: There has been an increase in awareness about antibiotic resistance in recent years owing to which patients are increasingly demanding antibiotics that can effectively treat their infections. This is expected to drive the demand for cefprozil API in the coming years.
- . 5 Emerging markets offer lucrative opportunities: The emerging markets offer lucrative opportunities due their large population base and untapped potentials In terms of sales revenue generated from sales of drugs such as CefProcil APIs
Scope Of The Report
Report Attributes
Report Details
Report Title
Cefprozil API Market Research Report
By Type
Purity ≥ 98 %, Purity ≥ 99 %
By Application
Cefprozil Tablets, Cefprozil Suspension
By Companies
Luoxin Pharmaceutical, Dhanuka Laboratories, Reva Pharma, Nishchem International, Orchid Pharma, Virchow Healthcare, Canagen Pharmaceutical, Athos Chemicals, Lupin, ACS Dobfar, Luoxin Pharmaceutical, Nectar Lifesciences, Qilu Pharmaceutial
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
220
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Cefprozil API Market Report Segments:
The global Cefprozil API market is segmented on the basis of:
Types
Purity ≥ 98 %, Purity ≥ 99 %
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cefprozil Tablets, Cefprozil Suspension
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Luoxin Pharmaceutical
- Dhanuka Laboratories
- Reva Pharma
- Nishchem International
- Orchid Pharma
- Virchow Healthcare
- Canagen Pharmaceutical
- Athos Chemicals
- Lupin
- ACS Dobfar
- Luoxin Pharmaceutical
- Nectar Lifesciences
- Qilu Pharmaceutial
Highlights of The Cefprozil API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity ≥ 98 %
- Purity ≥ 99 %
- By Application:
- Cefprozil Tablets
- Cefprozil Suspension
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cefprozil API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cefprozil API is a medication used to treat bacterial infections. It works by stopping the growth of bacteria.
Some of the key players operating in the cefprozil api market are Luoxin Pharmaceutical, Dhanuka Laboratories, Reva Pharma, Nishchem International, Orchid Pharma, Virchow Healthcare, Canagen Pharmaceutical, Athos Chemicals, Lupin, ACS Dobfar, Luoxin Pharmaceutical, Nectar Lifesciences, Qilu Pharmaceutial.
The cefprozil api market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cefprozil API Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Cefprozil API Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Cefprozil API Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Cefprozil API Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Cefprozil API Market Size & Forecast, 2018-2028 4.5.1 Cefprozil API Market Size and Y-o-Y Growth 4.5.2 Cefprozil API Market Absolute $ Opportunity
Chapter 5 Global Cefprozil API Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cefprozil API Market Size Forecast by Type
5.2.1 Purity ≥ 98 %
5.2.2 Purity ≥ 99 %
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cefprozil API Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cefprozil API Market Size Forecast by Applications
6.2.1 Cefprozil Tablets
6.2.2 Cefprozil Suspension
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cefprozil API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cefprozil API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cefprozil API Analysis and Forecast
9.1 Introduction
9.2 North America Cefprozil API Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cefprozil API Market Size Forecast by Type
9.6.1 Purity ≥ 98 %
9.6.2 Purity ≥ 99 %
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cefprozil API Market Size Forecast by Applications
9.10.1 Cefprozil Tablets
9.10.2 Cefprozil Suspension
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cefprozil API Analysis and Forecast
10.1 Introduction
10.2 Europe Cefprozil API Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cefprozil API Market Size Forecast by Type
10.6.1 Purity ≥ 98 %
10.6.2 Purity ≥ 99 %
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cefprozil API Market Size Forecast by Applications
10.10.1 Cefprozil Tablets
10.10.2 Cefprozil Suspension
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cefprozil API Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cefprozil API Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cefprozil API Market Size Forecast by Type
11.6.1 Purity ≥ 98 %
11.6.2 Purity ≥ 99 %
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cefprozil API Market Size Forecast by Applications
11.10.1 Cefprozil Tablets
11.10.2 Cefprozil Suspension
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cefprozil API Analysis and Forecast
12.1 Introduction
12.2 Latin America Cefprozil API Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cefprozil API Market Size Forecast by Type
12.6.1 Purity ≥ 98 %
12.6.2 Purity ≥ 99 %
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cefprozil API Market Size Forecast by Applications
12.10.1 Cefprozil Tablets
12.10.2 Cefprozil Suspension
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cefprozil API Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cefprozil API Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cefprozil API Market Size Forecast by Type
13.6.1 Purity ≥ 98 %
13.6.2 Purity ≥ 99 %
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cefprozil API Market Size Forecast by Applications
13.10.1 Cefprozil Tablets
13.10.2 Cefprozil Suspension
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cefprozil API Market: Competitive Dashboard
14.2 Global Cefprozil API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Luoxin Pharmaceutical
14.3.2 Dhanuka Laboratories
14.3.3 Reva Pharma
14.3.4 Nishchem International
14.3.5 Orchid Pharma
14.3.6 Virchow Healthcare
14.3.7 Canagen Pharmaceutical
14.3.8 Athos Chemicals
14.3.9 Lupin
14.3.10 ACS Dobfar
14.3.11 Luoxin Pharmaceutical
14.3.12 Nectar Lifesciences
14.3.13 Qilu Pharmaceutial